ArticleHarm reduction journal2025
Community-based drug checking at syringe service programs in New York City observe an increasing prevalence of xylazine from 2021 through 2024.
Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026Review
- Emergency department-based testing for xylazine and other novel psychoactive substances in Central Alabama: a feasibility study.Harm reduction journal · 2026Article
- Perceptions and Experiences of Xylazine, Disparities in Xylazine Awareness, and Correlates of Xylazine-Attributed Wounds Among People Who Use Opioids.International journal of environmental research and public health · 2026Article
- Align Appalachia's Opioid-Settlement Spending with Evidence and Emerging Threats.Journal of Appalachian health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundXylazine has emerged as a major component of the unregulated opioid supply in several jurisdictions across the United States. However, the extent of xylazine in local drug supplies is unknown. Drug checking is a harm reduction strategy that provides information to people who use drugs and allows for insight into the composition of local drug supplies.
methodsThe New York City Department of Health and Mental Hygiene (DOHMH) worked with syringe service program (SSP) partners to operate a drug checking pilot study that continued as a public health program. Drug samples were submitted by SSP participants for drug checking by trained DOHMH staff and further testing by secondary laboratory partners. The secondary laboratory used both GC/MS and LC-QTOF-MS to identify compounds present in a drug sample.
resultsDrug samples collected from November 2021 through December 2024 were analyzed. There were N = 1027 secondary laboratory testing results that contained opioids. Of these, n = 449 (43.7%) also contained xylazine. The prevalence of opioids containing xylazine increased from 10.7% in 2021 to 53.7% through 2024. Visualization of the monthly xylazine prevalence, as well as an accompanying chi-square test for trend in proportions (χ
conclusionThe prevalence of xylazine in samples containing opioids has increased in New York City from November 2021 through December 2024. Drug checking can monitor changes in the local drug supply and inform existing harm reduction efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.